(3beta,13E,14alpha)-13-{2-[2-(二甲基氨基)乙氧基]-2-氧代乙亚基}-14-甲基-7-氧代罗汉松n-3-基3-羟基-3-甲基丁酸酯 | 26241-81-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: (3beta,13E,14alpha)-13-{2-[2-(二甲基氨基)乙氧基]-2-氧代乙亚基}-14-甲基-7-氧代罗汉松n-3-基3-羟基-3-甲基丁酸酯
• 中文别名: 考明碱
• 英文名称: [3β-(β-hydroxy-isovaleryloxy)-7-oxo-14α-methyl-podocarpanylidene-(13seqtrans)]-acetic acid-(2-dimethylamino-ethyl ester)
• 英文别名: [3β-(β-Hydroxy-isovaleryloxy)-7-oxo-14α-methyl-podocarpanyliden-(13ξ)]-essigsaeure-[2-(acetyl-methyl-amino)-aethylester]；[3β-(β-Hydroxy-isovaleryloxy)-7-oxo-14α-methyl-podocarpanyliden-(13seqtrans)]-essigsaeure-(2-dimethylamino-aethylester)；N-Acetyl-coumingidin；Coumingin；Coumingine；[(2S,4aR,4bS,7E,8R,8aS,10aR)-7-[2-[2-(dimethylamino)ethoxy]-2-oxoethylidene]-1,1,4a,8-tetramethyl-9-oxo-2,3,4,4b,5,6,8,8a,10,10a-decahydrophenanthren-2-yl] 3-hydroxy-3-methylbutanoate
• CAS: 26241-81-6
• 化学式: C₂₉H₄₇NO₆
• 分子量: 505.695
• InChiKey: LSUIBLFFCBWTAR-ZSTRPFQBSA-N

物化性质

• 熔点：
  142°
• 比旋光度：
  D20 -70°
• 沸点：
  596.1±50.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  93.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (3beta,13E,14alpha)-13-{2-[2-(二甲基氨基)乙氧基]-2-氧代乙亚基}-14-甲基-7-氧代罗汉松n-3-基3-羟基-3-甲基丁酸酯 在 chromium(VI) oxide 、 氢氧化钾 、 戊醇 、 sodium 、 一水合肼 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 反应 2.0h， 生成 3-Oxo-cassan-19-saeure
  参考文献：
  名称：

  祖尔Kenntnis DER格木属-Alkaloide。17. Mitteilung。联邦储蓄银行的最佳豁免权19世期衍生品

  摘要：

  为了进行比较，已经制备了3β-和7β-羟基cassan-19-oic酸（分别为V a和VIa）。还描述了衍生自卡萨因的两种三醇XI和XII。

  DOI：

  10.1002/hlca.19610440622
• 作为产物：
  描述：

  乙酸酐 、 alkaline earth salt of/the/ methylsulfuric acid 在 吡啶 作用下， 生成 (3beta,13E,14alpha)-13-{2-[2-(二甲基氨基)乙氧基]-2-氧代乙亚基}-14-甲基-7-氧代罗汉松n-3-基3-羟基-3-甲基丁酸酯
  参考文献：
  名称：

  MRI measurements of orbital tissues in dysthyroid ophthalmopathy

  摘要：

  Background: Muscle volume investigation by different imaging techniques has proven useful in the diagnosis and follow up of treatment in dysthyroid ophthalmopathy. However, no study on muscle volume measurement by magnetic resonance imaging (MRI) has been done in this disease. Methods: Six patients with monocular or asymmetric binocular dysthyroid ophthalmopathy and eight controls were examined with orbital MRI using a surface coil. In the muscle volume study, 2 mm coronal slices were used for measuring the six extraocular muscles (EOM), i.e., medial rectus (MR), lateral rectus (LR) superior rectus (SR), inferior rectus (IR), superior oblique (SO), and inferior oblique (IO) muscles, as well as the orbital fatty tissue (OFT). In the muscle thickness study, 3 mm transverse and sagittal images were used for measuring the four rectus muscles during fixation in different gaze positions in horizontal and vertical planes. Results: In dysthyroid ophthalmopathy, the muscle volume of the six external eye muscles was significantly larger than in controls, except for the IO. The IR and MR showed the largest increase in muscle volume. The correlation between muscle thickness and different degrees of eye deflections was linear for all four rectus muscles both in patients and controls, and no significant differences in the slopes of the regression lines were found. The volume of OFT was significantly larger in patients than in controls, and the change in volume was larger than that of muscle volume. Conclusions: MRI technique makes it possible to observe and evaluate quantitatively the volume of all six extraocular muscles and the orbital fatty tissue in dysthyroid ophthalmopathy. It also makes it possible to evaluate changes in morphology during eye muscle contraction.

  DOI：

  10.1007/s004170100352

文献信息

• Melanocortins are comparable to corticosteroids as inhibitors of traumatic ocular inflammation in rabbits
  作者：Nava Naveh、John Marshall

  DOI：10.1007/s00417-001-0379-1

  日期：2001.11

  Background: Melanocyte-stimulating hormone (MSH) is a known anti-inflammatory agent and we investigated whether it reduces the inflammatory reaction following ocular surgery. Methods: Rabbits received a perforating corneolimbal cut. Treatment involved topical (10(-8)M) or intramuscular (50 mg/kg/day) MSH, topical steroids or saline. The parameters studied were hyperemia. edema, aqueous protein levels and the number of inflammatory cells in the aqueous, as well as their number determined histologically in the injured cornea. Each parameter was assessed at 24 h post injury. Results: Topically and systematically applied MSH reduced edema to levels 60% and 76%, respectively, of those observed in operated saline-treated eyes (P <0.00 I), and their efficacy was comparable to that of topical steroids. The decrease in hyperemia brought about by MSH was more pronounced than that produced by steroids. Aqueous protein levels were reduced by a similar degree in the steroid- and MSH-treated eyes as in the saline group (P <0.001 for each treatment group); In MSH- and steroid-treated eyes the number of inflammatory cells in the aqueous was reduced by 80% and 50%, respectively. Conclusion: We demonstrated that MSH reduced the clinical signs of ocular inflammation. curtailed blood-aqueous barrier (BAB) disruption, and reduced aqueous inflammatory cell number. The efficacy of MSH applied systemically or topically was similar to that of steroids in reducing clinical signs of trauma, but MSH efficacy in maintaining BAB integrity surpassed that of steroids. We suggest that the melanocortins might be a useful anti-inflammatory agents in ocular trauma.
• Schlittler, Helvetica Chimica Acta, Engi-Festband <1941> 319, 328
  作者：Schlittler

  DOI：——

  日期：——
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• [EN] COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE INHIBITRICE DE L'ECOULEMENT, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：EASTMAN CHEM CO

  公开号：WO2007115181A9

  公开（公告）日：2008-04-03

  [EN] At least one compound chosen from compounds of Formula 1: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each Of R₂, R₃, R₄ and R₅ is independently chosen from -H, alkyl, substituted aikyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z' is chosen from -O-, -N-, -NO-, - NR₄-, -S-, -SO- and -SO₂-, wherein R₄ is defined as above; each of X, X', Y and Z is independently chosen from -CR₄R₅-, -NH-, -NR₄-, -NO-. -O-, -NOR₄-, -S-, -SO-, -SO₂-, wherein R₄ and R₅ are defined as above; R₁ is chosen from a tocopherol, a steroid and a flavonoid; and R₆, is chosen from any R₁, alkyl. substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
  [FR] La présente invention concerne au moins un composé choisi parmi les composés de formule 1 : un sel ou un ester pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, un chélate de celui-ci, un complexe non covalent de celui-ci, un promédicament de celui-ci et des mélanges de ces derniers, n étant un nombre de 1 à 900, les unités individuelles pouvant être identiques ou différentes, W étant choisi parmi l'alkyle, l'alkyle substitué, le cycloalkyle, le cycloalkyle substitué, l'aryle, l'aryle substitué, l'aralkyle et l'aralkyle substitué, R₂, R₃, R₄ et R₅ étant chacun indépendamment choisi parmi -H, alkyle, alkyle substitué, cycloalkyle, cycloalkyle substitué, aryle, aryle substitué, aralkyle et aralkyle substitué, Z' étant choisi parmi -O-, -N-, -NO-, - NR₄-, -S-, -SO- et -SO₂-, R₄ étant tel que défini ci-dessus, X, X', Y et Z étant chacun indépendamment choisi parmi -CR₄R₅-, -NH-, -NR₄-, -NO-, -O-, -NOR₄-, -S-, -SO-, -SO₂-, R₄ et R₅ étant tels que définis ci-dessus, R₁ étant choisi parmi un tocophérol, un stéroïde et un anthoxanthine, et R₆ étant choisi parmi R₁, alkyle, alkyle substitué, cycloalkyle, cycloalkyle substitué, aryle, aryle substitué, aralkyle et aralkyle substitué.
• MRI measurements of orbital tissues in dysthyroid ophthalmopathy
  作者：Yasuhiro Nishida、Suna Tian、Bengt Isberg、Leif Tallstedt、Gunnar Lennerstrand

  DOI：10.1007/s004170100352

  日期：2001.11

  Background: Muscle volume investigation by different imaging techniques has proven useful in the diagnosis and follow up of treatment in dysthyroid ophthalmopathy. However, no study on muscle volume measurement by magnetic resonance imaging (MRI) has been done in this disease. Methods: Six patients with monocular or asymmetric binocular dysthyroid ophthalmopathy and eight controls were examined with orbital MRI using a surface coil. In the muscle volume study, 2 mm coronal slices were used for measuring the six extraocular muscles (EOM), i.e., medial rectus (MR), lateral rectus (LR) superior rectus (SR), inferior rectus (IR), superior oblique (SO), and inferior oblique (IO) muscles, as well as the orbital fatty tissue (OFT). In the muscle thickness study, 3 mm transverse and sagittal images were used for measuring the four rectus muscles during fixation in different gaze positions in horizontal and vertical planes. Results: In dysthyroid ophthalmopathy, the muscle volume of the six external eye muscles was significantly larger than in controls, except for the IO. The IR and MR showed the largest increase in muscle volume. The correlation between muscle thickness and different degrees of eye deflections was linear for all four rectus muscles both in patients and controls, and no significant differences in the slopes of the regression lines were found. The volume of OFT was significantly larger in patients than in controls, and the change in volume was larger than that of muscle volume. Conclusions: MRI technique makes it possible to observe and evaluate quantitatively the volume of all six extraocular muscles and the orbital fatty tissue in dysthyroid ophthalmopathy. It also makes it possible to evaluate changes in morphology during eye muscle contraction.